A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

NCT07740486 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

248

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma (MM)

Interventions

DRUG: Teclistamab
DRUG: Talquetamab
DRUG: Daratumumab (Subcutaneously)
DRUG: Lenalidomide

Sponsor

Polish Myeloma Consortium

Collaborators

[object Object]
[object Object]